Mesenchymal stromal cells (MSCs) have immunomodulatory effects and are increasingly being used for the treatment of acute and chronic GVHD. Although they seem immuno-privileged, they induce alloresponses, but the risk of immunization is poorly characterized. After infusion, they first reach the lungs, liver and spleen, and are then difficult to trace. Several mechanisms are involved in stromal cells suppressing alloreactivity, such as induction of regulatory T cells, but whether or not this will also affect leukemic relapse or increase infections is not known. Although several encouraging pilot studies have been published, there have been few prospective randomized trials. There may be a bias in the literature, as negative results are seldom published, and there have been few comparative studies with other immunosuppressive regimens. Most animal models have failed to show any effect on GVHD. Several questions remain to be answered for optimization of stromal cell therapy. Which source is optimal-BM, fat, cord or decidua? Can stromal cells be replaced by exosomes, which culture conditions are most appropriate and at what passage and how frequently should cells be administered? More research is required to move stromal cell therapy forward to become an established treatment for acute and chronic GVHD.
INTRODUCTION
Stromal cells support the integrity of tissues and provide growth factors for regeneration. Depending on their local distribution, stromal cells have different assignments. In the BM, mesenchymal stromal cells (BM-MSCs) support hematopoietic cell development, 1 whereas decidual stromal cells (DSCs) in the placenta promote trophoblast invasion and therefore implantation of the developing fetus. 2 DSCs are also important for the development of feto-maternal tolerance. 3, 4 Stromal cells have immunosuppressive capacity, [5] [6] [7] which paved the way for using them in the treatment of inflammatory diseases. Owing to their low immunostimulatory effect, allogeneic third-party stromal cells are often used.
After our first report on the treatment with BM-MSCs of a 9-year-old boy with refectory GVHD who miraculously improved, 8 there were high expectations for these cells for the treatment of inflammatory disorders and in regenerative medicine. Unfortunately, this patient died of pneumonia 19 months after transplantation. 9 Ten years later, we wonder whether stromal cells have solved anything. Have they really saved the lives of any GVHD patients?
Several concerns have been raised regarding the use of allogeneic stromal cells (Table 1) . It is often stated that MSCs are immunoprivileged, and are unable to induce alloresponses, 10, 11 but stromal cells constitutively express MHC class I, and do indeed induce proliferation of allogeneic lymphocytes. 6 Beggs et al. 12 showed that baboons produced alloantibodies after administration of allogeneic BM-MSCs, indicating that they can immunize the host. Furthermore, allogeneic BM-MSCs are rejected in MHC-mismatched murine recipients 13 and they can induce memory T-cell responses, resulting in the rejection of allogeneic stem cell grafts.
14 Thus, MSCs are not intrinsically immunoprivileged. Sundin et al. 15 detected no anti-HLA Abs when analyzing 12 GVHD patients after MSC infusion, but confirmatory studies are needed. Patients with acute GVHD are heavily immunosuppressed, but patients with functional immune systems may respond differently and develop multi-specific anti-HLA Abs. There are limited data on the homing capacity of MSCs in patients, and most studies on cell distribution have been confined to animal models. Intravenously infused cells first reach the lungs and then redistribute to the liver and spleen, 16 whereas there is little proof of specific homing to inflamed tissue. 9 Autopsy examinations have revealed that BM-MSCs can be detected in the lungs and lymph nodes of some patients, but at low levels. 9, 17 Thus, MSCs hardly seem to engraft, but rather may mediate their function through paracrine factors before they are rejected.
As engraftment of BM-MSCs is rare, one might wonder if they even survive in the short term after infusion. Culture expanded fibroblast-like cells may not be adapted to survive in blood, which contains coagulation and complement factors. It has been shown that BM-MSCs are susceptible to complement activation after contact with human blood, 18 which results in cell dysfunction or cell death. 19 BM-MSCs also elicit the formation of clotting factors when in contact with blood. 20 The immunosuppressive capacity of MSCs may not only be a positive feature when treating patients who are already highly susceptible to infections. Co-infusion of BM-MSCs with cord blood transplantation delays immune reconstitution, as shown by lower levels of T-cell receptor excision circles and serum IgG and IgM. 21 It has further been found to be associated with the development of EBV-related post-transplant lymphoproliferative disorder, 9, 22 and invasive fungal infections. 23 There are also worries that MSCs may promote cancer cell growth. Co-transplantation of BM-MSCs was found to be associated with a higher rate of occurrence of leukemic relapse. 24 BM-MSCs have also been suggested to be involved in the progression of oncogenesis in multiple myeloma, 25 which can be mediated by MSC-derived exosomes. 26 The anticipation of using BM-MSCs as GVHD treatment dramatically declined in the scientific community when the negative results of the randomized clinical trial by Osiris Therapeutics were released. 27 BM-MSC administration for treatment of GVHD did not improve long-term survival 23 and have also failed to show effects on GVHD in animal models. [28] [29] [30] [31] [32] Some studies from academic institutions have shown positive results, but there is most likely a selection bias in the literature as negative results are seldom published. 33 With all these concerns in mind, should we really use stromal cells as treatment for GVHD? Before we condemn this kind of therapy, we will summarize what we know today.
THE DEVELOPMENTAL ORIGIN OF MSCS
The mesodermal precursors that give rise to the in vitro expanded multipotential MSC lines have not been identified, and where they reside in vivo is still not clear. The fact that MSCs and MSC-like cells can be isolated from many different tissues, including BM, fat and placenta, suggests that there is a common reservoir of these cells in the body (reviewed in Murray et al. 34 ). However, whether all MSCs are phenotypically and functionally equivalent and how in vitro expansion affects these features is not known. Recent advances suggest that at least subsets of MSCs are anatomically and functionally associated with vascular niches. 35, 36 MSCs can also be isolated from avascular tissues, such as the amniotic membrane, but these still show an inherent capacity to promote angiogenesis. 37 Pericytes surround endothelial cells in blood microvessels and contribute to vascular development, stabilization and remodeling. 34 Pericytes have been shown to have MSC-like features, including multipotency 38, 39 and immunosuppressive capacities. 40 A vascular origin of MSCs may be a positive trait in the context of blood compatibility after infusion, but in vitro expansion of the cells can still affect the phenotype and function of MSCs.
IMMUNE MODULATION BY MSCS
The immunomodulatory properties of MSCs have been extensively studied over the past 10 years, and there are already several detailed reviews covering characterization, immune modulation and tissue regeneration by MSCs. [41] [42] [43] [44] [45] In this section, we will briefly discuss some of these properties, which are summarized in Table 2 .
One prerequisite for the introduction of BM-MSCs as treatment for GVHD was their ability to suppress alloreactivity in mixed lymphocyte reactions. 5, 10, 11, 46, 47 This anti-proliferative ability is shared by all stromal cells, including placental stromal cells 6 and skin fibroblasts. 7 Despite the fact that MSCs reduce alloreactivity in vitro, it has been difficult to correlate clinical outcome to successful inhibition of mixed lymphocyte reactions with BMMSCs and patient PBMCs as responder cells. 48 MSCs use a variety of different factors in order to suppress immune responses, many of which are secreted. Some of these factors are constitutively produced by MSCs, such as HLA-G5, 49 prostaglandin E 2 (PGE 2 ), 50 and galectins. 51 The immunomodulatory effects exerted by MSCs can be augmented if the cells are activated by cytokines such as IFN-g. [52] [53] [54] It has also been shown that MSCs can be activated by stimulation of their Toll-like receptors. 55 Another important mediator of suppression by stromal cells is the T-cell inhibitory enzyme indoleamine-2,3-dioxygenase (IDO). 56 IDO expression can be induced by IFN-g 57 and by activation of TLR-3.
55,58 MSC-produced IDO is involved in the induction of regulatory T cells and inhibition of Th17 differentiation. 59, 60 MSCderived IDO can also promote differentiation of macrophages toward an M2 phenotype. 61 Activated MSCs can modulate adaptive immune cells through contact-dependent mechanisms. These include activation of the PD-1 pathway, 62 Fas-mediated T-cell apoptosis, 63 engagement of 
CD39 and CD73
Adenosine-mediated suppression of T cells
VCAM-1 and ICAM-1, 64 and through upregulation of CD39 and increase in adenosine production. 65 Although IDO is important in the T-cell suppression by MSCs in a human setting, synthesis of nitric oxide is also induced by IFN-g, which has been shown to be a main mediator of suppression in mice. 54 This demonstrates the variation among different species regarding the mechanisms of immune suppression by MSCs and the translational difficulties that might occur when validating a new MSC therapy in animal models. 66 MSCs may need to be licensed by IFN-g or nitric oxide, or transduced with IL-10 to ameliorate GVHD and improve survival in mouse models. 31, 54, 67 STROMAL CELL-DERIVED EXOSOMES AND MICROVESICLES Exosomes and microvesicles are small but complex entities that contain both immunomodulatory proteins and microRNA, and have homing abilities. 68 They are secreted by live cells and are involved in cell-cell communication and transfer of cellular material. Depending on the intracellular origin, secreted membrane vesicles can have distinct biochemical properties which probably also affect their function. True exosomes derive from multivesicular bodies and measure 50-100 nm in diameter. 69 MSC-derived microvesicles have been shown to protect from acute kidney injury, 70 myocardial ischemia 71 and pulmonary hypertension 72 in animal models ( Table 3 ). The regenerative capacities of microvesicles appear to be at least partly dependent on the mRNA cargo, as treatment with RNAase to inactivate the mRNA content abrogated the protective effects. 73 Some advantages of exosomes and microvesicles are that they may be more defined and with more controlled functions compared with viable cells, and that they can deliver target molecules intracellularly. 74 Microvesicles derived from MSCs were also demonstrated to inhibit tumor growth. 75 Exosomes may be ideal carriers of the intricate blend of paracrine factors that are needed for treatment of a complicated disease such as GVHD. One case where exosomes were used for treatment for severe acute GVHD has been reported in an abstract that was presented at the EBMT meeting in 2013. 76 However, if therapeutic exosomes are to be translated into clinical use, there are still major concerns that need to be resolved. The isolation of exosomes must be improved to be cost effective, and the yield and purity of the product need to be increased. 77, 78 In addition, the exosome product obtained by the most common isolation protocol with differential centrifugation and a sucrose gradient yield a heterogeneous product. Therefore, an exosome or microvesicle product needs to be extensively characterized in order to assess its biological function before it can be used therapeutically.
CLINICAL USE OF BM-DERIVED MSCS
Needless to say, steroid-refractory severe acute or chronic GVHDs are terrible disorders where little therapeutic progress has been made over the last three decades. [79] [80] [81] We were the first group to use MSCs for the treatment of life-threatening acute GVHD, and we reported dramatic responses in some patients, but unfortunately not all. 8, 9 These results encouraged a multi-centre phase-II study involving five centres and 55 patients. 82 Complete response was seen in 68% of the children and in 53% of the adult patients. There was no difference whether the MSCs were from an HLA-identical sibling donor, a haploidentical donor or a third party. More than 200 patients have been reported to be treated for acute GVHD ( Table 4 ). The MSC dose has ranged from 1 to 21 doses. Complete response has been seen in 52% of the patients, with partial response in 23% and no response in 25%. 83 Most centres used MSCs expanded in FCS, but expansion of MSCs in platelet lysate medium and human AB serum was also reported. 84, 85 There have been few randomized studies using MSCs. Osiris Therapeutics, Inc. used expanded MSCs, Prochymal, for acute GVHD of grades II-IV. 86 Initial response was 94%, with a complete response of 77%.
Subsequently, a prospective double-blind placebo-controlled phase-III study was performed in patients with acute GVHD of grades II-IV using Prochymal in two patients for every one who received placebo. 87 Durable complete response was 40% in the Prochymal group and 28% in the placebo group (P ¼ 0.08). Of 61 patients with acute GVHD of the liver, complete response was 76% in the Prochymal group and 47% in the placebo group (Po0.05). In patients with acute gastrointestinal GVHD, complete response was also more common in the Prochymal group than in the placebo group (Po0.05). There have been few long-term reports using MSCs. At our centre, 31 patients treated with MSCs for acute GVHD or hemorrhagic cystitis were followed for 44 years. 48 The patients who received MSCs from passage 1-2 had better survival (75% at 1 year) than those who received MSCs from passage 3-4 (21%) (Po0.01). Long-term survival was not better than in patients with severe acute GVHD who were not treated with MSCs. 23 
ALTERNATE SOURCES OF CELLS FOR ACUTE GVHD
As an alternative to BM-derived MSCs, adipose tissue-, umbilical cord-or placental tissue-derived stromal cells have been used for the treatment of acute GVHD 88, 89 (Table 5 ). We recently introduced DSCs from term fetal membrane as a treatment for patients with GVHD. 90 We first compared three different sources of cells from the placenta: DSCs, stromal cells from umbilical cord and stromal cells from placental villi in vitro. 6 We found that DSCs exerted the most consistent inhibition of proliferation and inhibition of IFN-g and IL-17 production in mixed lymphocyte reactions compared with BM-MSCs and the other sources of stromal cells from placenta. Other major advantages with this cell population are the great expansion potential at low passage and high expression of integrins. 6, 52 We therefore used DSCs for treatment of severe steroid-refractory acute GVHD of grades III-IV in nine patients. 90 Median age was 57 years and two patients had a complete response and four had a partial response.
A number of other cell subsets have been suggested as treatment for GVHD, for example, CD4
þ regulatory T cells, 91 myeloid-derived suppressor cells 92 and CD8 þ regulatory T cells 93 ( Table 5 ). The target of these cell types is the suppression of alloreactivity, while MSCs and cells isolated from the placenta may also have regenerative abilities. The effect on tissue regeneration by MSCs in the GVHD setting has not been thoroughly investigated.
STROMAL CELLS FOR TREATMENT OF CHRONIC GVHD
Stromal cells have also been used for treatment of chronic GVHD. In the first patient treated, we saw a partial response. 9 The largest study was from Weng et al. 94 who reported on 19 patients with refractory chronic GVHD. These patients were treated with 1-5 doses. A response was seen in 14 of the 19 patients (74%). Of the 61 patients reported to have been treated with MSCs for chronic GVHD, complete response was seen in 26% of the patients, partial response was seen in 48% of the patients and 26% of the patients did not respond at all (Table 4) . 83 
STROMAL CELLS FOR PREVENTION OF GVHD
Lazarus et al. 95 were the first to show that it was safe to give HLA-identical MSCs to allogeneic HSCT recipients. No acute side effects were seen after infusion of MSC doses at a range of 1-5 Â 10 6 cells/kg in 46 HLA-identical sibling transplant recipients. Bernardo et al. 96 used MSCs at the time of HSCT transplantation in children who were recipients of cord blood grafts. Ball et al.
97
performed co-transplantation of MSCs in children undergoing haploidentical HSCT. Compared with retrospective controls, they saw less graft failure and faster engraftment of platelets using MSCs. In a prospective randomized study, patients undergoing HSCT from haploidentical donors were randomized to co-infusion with MSCs (3-5 Â 10 5 cells/kg) or not. The MSC group reached platelets more than 50 Â 10 9 /L at a median of 22 days, as compared with 28 days in the control group (P ¼ 0.04). 98 Acute GVHD and survival were not statistically significantly different between the groups. 98 Kuzmina et al. 99 performed a randomized prophylactic study with an MSC dose of 1 Â 10 6 /kg at the time of blood count recovery. Acute GVHD of grades II-IV developed in only 5% of the MSC patients as compared with 39% of the controls (P ¼ 0.002).
DISCUSSION
When a new experimental treatment is introduced, only severely ill patients-where there is little to lose-are included. 8, 9 A 50% response rate among end-stage acute GVHD patients may seem encouraging (Table 4) . However, an improved survival was only noted in patients with complete response, 82 for whom 2-year survival was 53% and long-term survival even worse. 48 The results are more promising when used at an early stage of GVHD. 86 Bernardo et al. 96 treated grade-II acute GVHD with MSCs and reported no deaths that were attributable to acute GVHD as compared with 26% in retrospective control patients. According to animal data, not only early treatment, but also repeated doses may be needed. Although many patients respond well to one dose, some patients appear to benefit from several doses to maintain immunosuppression. 100 Stromal cells may also be used for chronic GVHD, but they should probably be used before fibrosis occurs. 101 Stromal cells have a profound effect on coagulation, 18, 20 which partly explains their effectiveness in stopping major hemorrhages. 90, 102, 103 BM must be accessed by aspiration, and this source of MSCs has been challenged by MSCs from adipose tissue, umbilical-cordderived MSCs and stromal cells from the placenta-such as DSCs. Placental stromal cells are accessible without any invasive procedure and with little ethical consideration. To determine which source of stromal cells is superior would require large prospective randomized studies that may never be performed.
Although no acute toxicity has been reported, the coagulation system is activated 18, 20 and there is a concern regarding pulmonary embolism. 104 Patients treated with stromal cells need to be followed closely for the possible risk of tumor formation. 25, 26, [105] [106] [107] [108] When taking all clinical observations into consideration, we still believe that stromal cell therapy can be useful for GVHD, particularly in children. However, this treatment needs to be optimized, combining it with the right immunosuppressive therapies. We need to learn more about the therapeutic potential of stromal cells in order to understand their mechanistic functions Adipose tissue 83, 88 Umbilical cord 83, 89 Placenta-derived decidua 83, 90 Exosomes from stromal cells 76 Expansion media FCS 8, 9, [82] [83] [84] [85] [86] [87] Platelet lysate medium 83, 85 AB serum 84 Regulatory T cells CD4 þ in the clinical setting. We have learnt that they are immunosuppressive and that they have regenerative properties, but so far these traits have only been confirmed in vitro. Whether or not the stromal cells need to localize to the affected organ or whether the systemic effect is sufficient is also unclear. Much more researchmechanistically in vitro, in vivo in experimental animals, and also in the clinic-is required to establish stromal cell therapy as an effective treatment for GVHD.
